Keytruda

Merck Reports Progress On The Cancer Front As It Prepares For Keytruda Patent Expiration

Bernie Sanders Blasts Big Pharma's Pricing Of Lifesaving Drugs In US During Senate Hearing On Medicare

Investor Optimism Around Keytruda Drives Merck Stock To Golden Cross Ahead of Earnings

Bernie Sanders Blasts Big Pharma's Pricing Of Lifesaving Drugs In US During Senate Hearing On Medicare

Investor Optimism Around Keytruda Drives Merck Stock To Golden Cross Ahead of Earnings

Merck Q2 Earnings Preview: Analyst Expectations, Jim Cramer's View, And The Spotlight On Keytruda

EXCLUSIVE: eFFECTOR Therapeutics Announces SPAC Deal To Advance Cancer-Fighting Pipeline

Merck Q2 Earnings Preview: Analyst Expectations, Jim Cramer's View, And The Spotlight On Keytruda

EXCLUSIVE: eFFECTOR Therapeutics Announces SPAC Deal To Advance Cancer-Fighting Pipeline

Goldman Sachs Upgrades Merck On Cancer, HIV, COVID-19 Pipeline

Merck Analysts Focus On Fundamentals, Keytruda Strength Following Guidance Cut

Keytruda Recent News

What Drove Merck's Keytruda Shortfall In Q4

What's Behind PDS Biotech's Rally?

Merck's Keytruda Gets A Double Dose Of Positive News

Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates

Merck's Keytruda Vs. Bristol-Myers Squibb's Opdivo In Q1 And Beyond

Iovance Issues Cancer Trial Updates Ahead Of ASCO Meeting, Sending Stock Skyward

Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

Bristol-Myers Squibb Withdraws Regulatory Application For Lung Cancer Combo Drug

Attention Biotech Investors: Mark Your Calendar For These January PDUFA Dates

Attention Biotech Investors: Mark Your Calendar For These December PDUFA Dates

Merck Is Up 40% In 2018: What's Driving The Rally?

Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates

Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates

Merck, Bristol Myers Shares Move On Alleged FDA Alert On Keytruda

Incyte Falls 20% After Cancer Drug Fails Phase 3 Trial

Attention Biotech Investors: Mark Your Calendar For These April PDUFA Dates

Early Keytruda Results Win Merck An Upgrade

The Bull Thesis For Merck Is Evaporating

Analyst Grows Cautious On Merck's Keytruda

Boosted By Keytruda, Citi Upgrades Merck To Buy For The First Time Ever

Ahead Of Earnings: Why You Should Be Buying Merck And Selling Bristol-Myers

Tracking The Busy June PDUFA Calendar

The Most Notable Abstracts Released Ahead Of ASCO 2017